Introduction
Chronic lymphocytic leukaemia (CLL) is characterised by the accumulation of long-lived, mature neoplastic B-lymphocytes in blood and tissues. 1, 2 It is believed that prolonged in vivo survival of malignant cells contributes to their clonal expansion. 3, 4 The fact that the malignant cells, despite progressively accumulating in vivo, rapidly undergo apoptosis when cultured in vitro implies that microenvironmental factors are likely to play a prominent role in prolonging the lifespan of CLL cells.
VEGF is one factor that could potentially be important for the pathogenesis and prognosis of CLL. CLL cells themselves produce VEGF, 5, 6 and high levels of this growth factor in serum, 7 as well as high expression of VEGF receptor (VEGFR)-2 on the malignant cells, 8 correlate with shortened patient survival. Moreover, in a previous study, 5 we observed increased vascularisation in enlarged lymph nodes of CLL patients and proposed that this was caused by paracrine stimulation of endothelial cells by CLL-cell-derived VEGF. Increased microvessel density has also been reported in the bone marrow of patients with CLL. 9 We suggested that increased angiogenesis might play an important role in the survival of tissue-phase CLL cells by providing metabolic support. 5 In addition to its role in angiogenesis, VEGF has been found to be an autocrine survival factor for some cell types including solid tumour and endothelial cells, [10] [11] [12] as well as CLL cells. 13 VEGF, like many other growth factors, often achieves its effects in cooperation with other stimuli. 14 An important microenvironmental factor affecting CLL-cell survival is CD40 ligand (CD154) expressed on activated T cells, monocytes, macrophages, dendritic cells and platelets. 15, 16 Its receptor CD40 is expressed by mature B-lymphocytes including CLL cells, and also by some nonhaemic cell types. 17 Stimulation of CD40 on endothelial cells, monocytes, fibroblasts and multiple myeloma cells upregulates production of VEGF by these cells. [18] [19] [20] Furthermore, neutralisation of autocrine VEGF by anti-VEGF antibody (Ab) completely abolished the mitogenic effect of CD154 on endothelial cells. 18 In CLL cells, ligation of CD40 by CD154 is known to inhibit spontaneous and drug-induced cell death. [21] [22] [23] [24] However, whether this effect also requires cell stimulation by the secreted autocrine VEGF is not known.
In the present study, we show that the previously observed promotion of CLL-cell survival by CD154 does indeed depend on autocrine VEGF production, and that both VEGFR and CD40 engagement are essential for this effect. We also show that VEGF provides a significant contribution to CD154-induced NF-kB activation and upregulation of survivin, one of the NF-kB target genes.
Materials and methods

Patients
All patients had typical CLL with high numbers of circulating malignant cells as defined morphologically (prolymphocytes o10%) and immunophenotypically (CD19 þ , CD5 þ , CD23 þ and weak light-chain-restricted surface immunoglobulin). Patients' samples were obtained after informed consent and with the approval of the Liverpool Research Ethics Committee. Relevant clinical and laboratory data of the patients studied are included as Supplementary information accompanying the paper.
Materials
Human VEGF Quantikine Colorimetric Sandwich ELISA (enzyme-linked immunosorbent assays) kit, anti-human VEGFneutralising monoclonal antibody (mAb) (MAB293), recombinant human VEGF165 and PLGF were all from R & D Systems (Abingdon, UK). Anti-human p65 mAb was from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The CD154 kit (ALX-850-064) containing recombinant human soluble CD154 trimeric protein (rhsCD154) and enhancer was from Alexis Biochemicals (San Diego, CA, USA). TransAM NF-kB p65 assay kit and nuclear extract kit were from Active Motif North America (Carlsbad, CA, USA). The NF-kB translocation inhibitor SN50, its control peptide (SN50M) and the VEGFR tyrosine kinase inhibitor SU5416 were from Calbiochem (Nottingham, UK 
Cell preparation and culture
Lymphocytes were isolated from heparinised PB by FicollHypaque density-gradient centrifugation and cryopreserved. Purified cells were always 495% CD19 positive. Frozen samples were rapidly thawed at 371C, slowly resuspended in RPMI-1640 medium containing 1% BSA, centrifuged, then resuspended in culture medium and incubated at 371C for at least 2 h prior to use.
Measurement of cell death
Determination of CLL-cell viability was based on the analysis of mitochondrial transmembrane potential with 3,3 0 dihexyloxacarbocyanine iodine (DiOC 6 ) and on cell-membrane permeability to propidium iodide (PI), as described previously. 25 Freshly thawed CLL cells were resuspended to 3 Â 10 6 /ml in RPMI-1640 medium containing 0.1% BSA and cultured in polyHEMA-coated 96-well plates (100 ml/well) at 371C in 5% CO 2 for up to 5 days. To determine cell survival, 100 ml of CLL-cell suspension was removed from culture at the indicated time points and incubated with 100 ml of 40 nM DiOC 6 for 20 min at 371C, and then incubated on ice for a further 30 min with an equal volume of 10 mg/ml PI. Cell viability was determined by flow cytometry using a FACScan.
Enzyme-linked immunosorbent assays
Secreted VEGF was measured using a human VEGF ELISA kit with a detection limit of 5.0 pg/ml. Survivin protein in total cell lysates was measured using a human Total Survivin ELISA kit with a detection limit of 3.6 pg/ml.
Evaluation of NF-kB activity
Cells were cultured with or without CD154 alone, with CD154 plus anti-VEGF-neutralising mAb or with CD154 plus SU5416 for 24 h. Nuclear extracts were prepared and their protein concentration determined by a Bradford-based assay (Bio-Rad). The DNA-binding activity of NF-kB was quantified using a TransAM NF-kB p65 transcription factor assay kit with a detection limit of 0.4 ng/ml.
Confocal microscopy
To confirm nuclear translocation of NF-kB, cytospins were prepared from cultured cells (300 r.p.m. for 3 min; Shandon Cytospin 2, Pittsburgh, PA, USA), air-dried and fixed in methanol for 10 min at RT. Fixed slides were washed in PBS and blocked for 1 h at RT with PBS containing human Ab, goat and mouse sera (all at 1%). After washing, mouse anti-human p65 mAb or nonspecific mouse IgG 1 mAb (2 mg/ml each diluted in PBS containing 1% human AB serum) was added and cells incubated for 1 h at RT. Goat anti-mouse-FITC conjugate (diluted 1:10 in 1% human AB serum/PBS) was added after further washing, cells incubated for 1 h at RT, washed and mounted in Vectashield. The cellular location of NF-kB p65 protein was then analysed by laser confocal microscopy using an Olympus BH2 microscope fitted with a Bio-Rad MR/AG2 Confocal Imaging System.
Results
CD154 stimulates VEGF production by CLL cells through a process involving NF-kB activation
Since it has been reported that CD154 enhances VEGF secretion by a number of cell types, [18] [19] [20] we first examined whether CD154 enhances VEGF production by CLL cells.
Using RT-PCR, we initially found that treatment of CLL cells with 200 ng/ml soluble trimeric CD154 for 6 h resulted in a twofold increase in VEGF mRNA expression (data not shown). We then assessed the effect of CD154 on CLL-cell production of VEGF protein. When cells from different CLL cases were cultured with 200 ng/ml CD154, this consistently caused an increase in VEGF secretion, which was first evident at 18 h, and persisted for up to 72 h. The highest relative increase compared with unstimulated cells was at 24 h and this incubation time was used in subsequent studies. Figure 1a shows the amounts of VEGF measured at 24 h in the supernatants of six different CLLcell clones cultured with or without CD154. The clear upregulation of VEGF secretion by CD154 seen in this figure was significant in all CLL cases tested (n ¼ 16, Po0.05).
Since NF-kB is a major pathway activated by CD40 engagement, 23 we next examined whether activation of NF-kB is required for the CD154-stimulated VEGF production. CLL cells were cultured in the presence or absence of CD154 alone, with CD154 plus the NF-kB inhibitor SN50 26 or with CD154 plus SN50M, an inactive analogue of SN50. SN50 is a cellpermeable inhibitor of nuclear translocation of NF-kB derived from the nuclear localisation sequence of its p50 component. As shown in Figure 1b , induction of VEGF by CD154 was significantly reduced by SN50 (Po0.01), but not by SN50M. This reduction was not due to nonspecific cytotoxicity of this reagent because, at the concentration used (18 mM), SN50 alone had no effect on the viability of CLL cells (data not shown).
Taken together, these results show that the upregulation of VEGF production by CLL cells in response to CD154 involves NF-kB activation.
VEGF production mediates the cytoprotective effect of CD154 on CLL cells
Having demonstrated that CD154 upregulates VEGF production by CLL cells, we next investigated whether VEGF plays a role in the cytoprotective effect of CD40 engagement.
Since it has been reported that cytoprotection by CD154 varies between CLL cases, 21, 27 we first examined 16 CLL clones for the antiapoptotic effect of CD40-CD154 interaction. In accordance with published data, 21, 27 only a proportion of the CLL clones (12 of 16 cases examined) showed a clear positive survival response, although all expressed VEGFR-1 and VEGFR-2 at both mRNA and protein levels (data not shown).
To determine whether VEGF is involved in this response, 10 CLL clones from this responder group were cultured for up to 6 days with or without CD154 7 inhibitors of VEGF or VEGFRs. In eight of the 10 CLL clones examined, a neutralising VEGF Taken together, these results demonstrate that VEGF mediated the antiapoptotic effect of CD154 in the 80% of cases in which such an effect was observed.
Increased secretion of VEGF alone is insufficient for CLL-cell rescue
Having established that CD154 induces NF-kB-dependent VEGF production by CLL cells and that secreted VEGF is involved in the prosurvival effects of CD40 ligation, we next examined how VEGF contributes to this cell rescue by CD154.
We first examined whether the addition of VEGF alone produces the same rescue effect as that observed with CD154. To eliminate potential effects of adhesion and cytokines on cell survival, CLL cells were cultured in polyHEMA-coated 96-well plates (3.3 Â 10 5 cells/100 ml/well) in serum-free medium (RPMI-1640 plus 0.1% BSA). During 3-day culture under these conditions, exogenous VEGF (100 ng/ml) had no effect on spontaneous cell death (Figure 3a) . Furthermore, a range of different concentrations of VEGF (1-500 ng/ml) had no effect on CLL-cell survival during culture for up to 7 days (data not shown). This suggests that the rescue effect of VEGF secreted in response to CD154 engagement is achieved through signalling that requires simultaneous engagement of both VEGFR(s) and CD40.
Basal autocrine VEGF provides some CLL-cell rescue through internal signalling Since CLL cells constitutively produce VEGF in culture, 5 we next investigated any potential prosurvival effects of this auotocrine VEGF. The effects of VEGF were blocked in two ways: by neutralising secreted VEGF with anti-VEGF mAb or by inhibiting VEGFR signalling.
Treatment with anti-VEGF mAb had no significant effect on the survival of cultured CLL cells (Figure 3b) . However, the VEGFR inhibitor SU5416 at a concentration of 10 mM caused a modest but significant decrease in cell survival (Figure 3c , Po0.001). Similar results were observed using 5 mM SU1498, another VEGFR inhibitor. We also treated cells with a combination of SU5416 and anti-VEGF mAb, but this did not have an any more pronounced effect on CLL-cell survival than SU5416 alone (data not shown).
Thus, although blocking secreted VEGF had no effect on CLLcell viability, the receptor tyrosine kinase inhibitors acting internally did shorten cell survival. This indicates the presence in cultured CLL cells of VEGFR-dependent signals for survival that cannot be blocked by neutralisation of secreted VEGF. Such divergent effects of external cytokine blockade versus receptorsignalling inhibition have been observed for other cell types.
29,12
Figure 1
Effect of CD154 on VEGF production by CLL cells. VEGF protein content in all supernatants was determined by ELISA. (a) CLL cells from six individual patients were cultured for 24 h in duplicate in the absence or presence of CD154 (200 ng/ml). Data are presented as means7s.d. of at least three separate experiments. Similar results were obtained in 10 additional cases. CD154 significantly induced VEGF production in all cases studied (Po0.01). (b) CLL cells were preincubated for 1 h with the NF-kB inhibitor SN50 (18 mM) or with its inactive analogue SN50M (18 mM), and then stimulated with CD154 (200 ng/ml) for 24 h. SN50 significantly inhibited CD154-induced VEGF production (Po0.05), while SN50M had no effect. The data are means7s.d. of seven CLL cases.
Figure 2
Role of VEGF in the antiapoptotic activity of CD154. CLL cells were incubated with anti-human VEGF mAb (1 mg/ml), IgG 2b as isotype control, SU5416 (10 mM) or DMSO (0.2% diluent for the SU5416) for 1 h prior to the addition of CD154 (200 ng/ml) as indicated in the figure. Cell viability was measured at day 4 of culture using DiOC 6 /PI staining followed by FACS analysis. Owing to the considerable variation in the viability of the control at day 4, the data are shown as relative viabilities compared with the control. The figure shows that the increase in cell viability induced by CD154 was greatly reduced by anti-VEGF or SU5416 (Po0.05). The results show the mean7s.d. of eight experiments involving eight different CLL-cell clones. The concentration of anti-VEGF mAb (1 mg/ml) was sufficient to inhibit all secreted VEGF measured in our study (20-220 pg/ml, see Figure 1 ) since, according to the supplier, 0.04-0.08 mg/ml of this mAb causes half-maximal inhibition of the effects of HUVEC stimulation by 10 ng/ml of rhVEGF.
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NF-kB activation by CD154 in CLL cells involves autocrine VEGF
A number of studies have shown that NF-kB mediates the antiapoptotic activity of CD154 in many cell types including CLL cells. 23, 30 We therefore next investigated whether the VEGF secreted in response to CD154 ligation contributes to CLL-cell rescue by activating NF-kB.
The NF-kB/Rel family includes five subunits: p65/RelA, p50, p52, c-Rel and RelB. The NF-kB components reported to be involved in CD154 signalling in CLL cells are p65, p50 and cRel, 23 whereas only p50/p65 heterodimer was found to be activated by VEGF in endothelial cells. 31 Therefore, in order to assess the contribution of VEGF to CD154-induced NF-kB activation, we measured p65 in nuclear extracts of CLL cells stimulated with CD154 in the presence or absence of VEGF blockade. Figure 4a shows that NF-kB was already activated in CLL cells and that CD154 increased this activation in each of the three cases tested. This increase was significantly reduced (Po0.05) or completely abolished by including anti-VEGF mAb or SU5416 in the cultures (Figure 4a) .
The role of VEGF in NF-kB activation in CLL cells stimulated by CD154 was confirmed by confocal microscopy. Cytospins made from untreated cells or from CLL cells cultured with CD154 alone, with CD154 plus SU5416, or with CD154 plus anti-VEGF mAb were stained with anti-p65 mAb (Figure 4b) . In untreated cells, p65 positivity was localised mainly outside the nucleus (I). In contrast, after 24 h culture with CD154, p65 was found largely in the nucleus (II). This nuclear translocation was almost completely abolished by SU5416 (III) or anti-VEGF mAb (IV). These data confirm that VEGF signalling is involved in the nuclear transport of NF-kB in CLL cells stimulated with CD154.
To determine which of the two VEGF receptors expressed by CLL cells has the capacity to mediate this NF-kB activation, we stimulated the cells with the receptor-specific ligands PLGF and VEGF-E. Both PLGF and VEGF-E are members of the VEGF protein family. PLGF binds to VEGFR-1 with high affinity but fails to bind to VEGFR-2, whereas VEGF-E binds specifically to VEGFR-2.
32,33 Figure 4c shows that both these ligands increased NF-kB activation in CLL cells, demonstrating that both VEGFR-1 and -2 can potentially be involved in VEGF signalling. However, since VEGF alone could not effectively protect cells from apoptosis (Figure 3) , NF-kB activation by VEGF alone does not explain the cytoprotection observed upon CD40 engagement. Rather a dual signal from both CD40 and VEGFRs is required.
VEGF is involved in the upregulation of survivin by CD154
Since a previous report implicated an increase in the production of the antiapoptotic protein survivin in the rescue of CLL cells by CD40 ligation, 27 we next examined to what extent VEGF contributes to this increased survivin production.
When CLL cells were cultured for periods of 24, 48 and 72 h in the presence or absence of CD154 (200 ng/ml), we found that the relative increase in survivin production was highest at 72 h (data not shown). This incubation period was then used in subsequent studies. Figure 5 shows that blocking VEGF receptor signalling with SU5416 significantly reduced the survivin expression induced by CD154 (Po0.05). Therefore, the survivin production implicated in cytoprotection by CD154 27 is at least partially dependent on VEGFR signalling. Effect of VEGF on CLL-cell survival. CLL cells were cultured in RPMI-1640 medium containing 0.1% BSA in polyHEMAcoated wells. Viability of harvested cells was measured by DiOC 6 /PI staining and flow cytometry. In (b and c), when no error bars are shown, the histograms are the means of two independent measurements, whereas all the other data were obtained from three or more repeated measurements. (a) CLL cells from seven separate individuals were cultured with or without 100 ng/ml VEGF for up to 3 days and the mean levels of cell survival were determined at the indicated time points. The data are shown as mean7s.d. The differences between levels of survival of control versus VEGF-treated cells were not significant. (b) Cells from six separate patients were cultured for up to 6 days in the presence of monoclonal anti-VEGF-neutralising mAb (1 mg/ ml) to abrogate the effects of endogenous VEGF; mouse IgG2b served as a control. Histograms represent mean values7s.d. for cells harvested at day 4 from each case studied. The differences between levels of viability for the control versus the anti-VEGF-treated cells were not significant. Similar results were obtained after 6 days. (c) CLL cells from the same six individuals in (b) were cultured with or without the VEGFR tyrosine kinase inhibitor SU5416 (10 mM) for up to 6 days. Histograms represent the mean values7s.d. for cells harvested at day 4. The viabilities of the control and SU5416-treated cells were significantly different (Po0.01). Similar results were obtained at day 6.
Discussion
We have previously shown that CLL cells secrete VEGF, which stimulates angiogenesis in a paracrine manner. 5 In the present study, we demonstrate for the first time that, in CLL cells, CD40 engagement by CD154 upregulates production of VEGF, and that this production at least partially depends on NF-kB activation. This is in accord with a number of previous studies implicating NF-kB in the upregulation of VEGF production in various other cell types. Thus, in human microvascular endothelial cells, NF-kB was found to be involved in the upregulation of VEGF mRNA and in the VEGF-dependent development of vessel-like structures in response to TNF-a. 34 Also, involvement of NF-kB in VEGF expression was found in prostate cancer cells and in breast cancer cell lines. 35, 36 In addition, it has been reported that NF-kB decoy oligonucleotides block the induction of VEGF in UV-irradiated skin cells 37 and that, in human macrophages, CD154 stimulation results in strong NF-kB-dependent VEGF induction. 38 We then examined the contribution of VEGF to the wellknown prosurvival effect of CD154 on CLL cells. 23, 27 This seemed important because a number of studies have shown that VEGF can support survival of different cell types. For example, VEGF prevents the in vitro apoptosis of endothelial cells induced by serum starvation, 39 and induces the expression of several antiapoptotic proteins in these cells. 40, 41 Moreover, an internal
Figure 4
Role of VEGF in CD154-induced NF-kB activation in CLL cells. (a) CLL cells from three separate cases were incubated with CD154 (200 ng/ml) in the absence or presence of SU5416 (10 mM), anti-VEGF mAb (1 mg/ml) or IgG 2b (1 mg/ml) as a control for the anti-VEGF. After 24 h, nuclear extracts were prepared and examined for the activation of NF-kB using the TransAM NF-kB p65 assay kit. (b) CLL cells were incubated for 24 h in the absence (I) or presence (II) of CD154, or CD154 plus SU5416 (III) or CD154 plus anti-VEGF mAb (IV) and stained with anti-p65 mAb. Fluorescent staining was analysed by confocal microscopy as described in Materials and methods. Note the translocation of activity to the nucleus in (II) and the inhibition of this translocation in (III) and (IV). Green fluorescence in the first columns shows endogenous p65. The second column is presented in false colour to show the signal intensity in the nucleus compared with the cytoplasm. Results shown are representative of three separate experiments. (c) CLL cells were incubated with VEGF receptor-specific ligands PLGF (VEGFR-1 specific, 100 ng/ml) and VEGF-E (VEGFR-2 specific, 50 ng/ml). The NF-kB activity was measured by the same method as in (a) (n ¼ 3).
Figure 5
Effect of VEGFR inhibition on CD154-enhanced survivin expression. CLL cells (8 Â 10 6 /ml) were treated with CD154 (200 ng/ ml) or CD154 plus SU5416 (10 mM) for 72 h, and survivin protein was measured by ELISA. The results show the mean7s.d. of six individual cases. Both the increase in survivin in the presence of CD154 and the subsequent reduction by SU5416 were statistically significant (Po0.05).
VEGF and CD154 in CLL-cell survival M Farahani et al autocrine loop has been identified as the mechanism for the regulation of haematopoietic stem-cell survival by VEGF. 12 As regards CLL cells, it has recently been reported that inhibition of VEGFR signalling by a green tea component epigallocatechin (EGCG) shortens in vitro survival of these cells. 13 Here, we show that blocking either VEGF itself or its receptors greatly reduces the survival-promoting effect of CD154 on CLL cells. However, in the absence of CD154, adding exogenous VEGF or blocking autocrine VEGF with an anti-VEGF mAb had no significant effect on cell survival. In contrast, the VEGF receptor inhibitor (SU5416) did shorten CLL-cell survival, suggesting the presence of an internal autocrine loop that cannot be inhibited by externally acting Ab. Such internal signalling has recently been described in malignant myeloid cells and haematopoietic progenitor cells. 29, 12 Since neither CD154 without VEGF nor VEGF alone could effectively rescue CLL cells from apoptosis, we propose that full cytoprotection requires cooperation of signals provided by these agents. However, since blocking VEGF and VEGFR did not completely reverse the cytoprotection provided by CD154, it is possible that some other factors induced by this agent (eg bFGF 42 ) also contribute to this cytoprotection.
As previous reports suggested that the increase in CLL-cell survival induced by CD154 largely depends on activation of NFkB, 23, 30 we next examined the contribution of VEGF to this activation. The effect of VEGF on the NF-kB pathway is largely dependent on cellular context. VEGF induces NF-kB activity in bovine retinal endothelial cells 43 and human vascular endothelial cells, 31 but inhibits NF-kB activation in haematopoietic progenitor cells. 44, 45 When we cultured CLL cells in the presence of CD154, this resulted in a sustained increase in the activation of NF-kB, which was abolished by either anti-VEGF mAb or SU5416. These results were confirmed by confocal microscopy showing nuclear translocation of NF-kB in response to CD154 and prevention of this translocation by inhibition of VEGF or its receptors. Taken together, these results indicate that, in CLL cells, NF-kB activation by CD154 is largely mediated by autocrine VEGF. However, since activation of the NF-kB pathway by VEGF alone was not sufficient to enhance CLLcell survival, the present results indicate that other signalling pathway(s) must also be involved in cytoprotection by CD154. This conclusion is in accord with gene-expression analyses showing the cooperation of multiple signalling pathways in CD40-regulated gene expression in B-lymphocytes. 46 Both VEGFRs and CD40 can generate other signals in addition to NF-kB activation and, moreover, CD40 can generate both proapoptotic and antiapoptotic signals. [47] [48] [49] Exactly how different signals induced by CD154 and VEGF cooperate to provide rescue of CLL cells was beyond the scope of the current study. However, It is known that CD40 ligation induces the production of antiapoptotic proteins including IAPs. In CLL cells, survivin has been reported to be the only IAP whose expression is induced by CD154. 27 Here, we confirm that CD40 engagement by CD154 upregulates survivin expression and, in addition, demonstrate that this upregulation is significantly reduced by blocking endogenous VEGF. We therefore suggest that the cytoprotective effect of CD154 is partially mediated through VEGF-dependent upregulation of survivin. This however does not exclude the involvement of other antiapoptotic proteins previously reported to be induced by CD40 ligation. 50 In conclusion, the present study for the first time demonstrates an autocrine function for CLL-cell-derived VEGF specifically linked to the regulation of cell survival by CD154. Moreover, we demonstrate that full cytoprotection of CLL cells by CD154 requires cooperation of signals generated by both CD40 and VEGFRs. Since the effects of CD40 ligation are thought to play a major pathogenetic role in CLL, pharmacological interference with the VEGF contribution to CD154 cytoprotection might be of therapeutic benefit.
